Damora Therapeutics
DMRA
25 hedge funds and large institutions have $30.5M invested in Damora Therapeutics in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 4 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.35% less ownership
Funds ownership: 41.17% → 39.81% (-1.4%)
18% less capital invested
Capital invested by funds: $37.2M → $30.5M (-$6.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$577K |
| 2 |
Renaissance Technologies
New York
|
+$400K |
| 3 |
Two Sigma Investments
New York
|
+$328K |
| 4 |
Two Sigma Advisers
New York
|
+$127K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$71.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$1.65M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$410K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$314K |
| 4 |
Millennium Management
New York
|
-$175K |
| 5 |
VF
Virtu Financial
New York
|
-$88K |
DMRA Hedge Fund Activity: Q4 2021 in Review
25 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q4 2021, worth a combined $30.5M — down 18% from $37.2M a quarter earlier.
Fund positioning in DMRA was balanced in Q4 2021: 4 funds opened new positions, 4 closed out, 8 added to existing stakes and 7 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $577K. The largest seller was Janus Henderson Group, cutting an estimated $1.65M.
- 25 institutional investors held Damora Therapeutics (DMRA) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $30.5M of Damora Therapeutics stock for Q4 2021, down 18% quarter-over-quarter.
- 4 funds opened new Damora Therapeutics positions in Q4 2021 and 4 closed out, a net change of 0 holders.
- The largest Damora Therapeutics buyer in Q4 2021 was Anson Funds Management, an estimated $577K added.
- The largest Damora Therapeutics seller in Q4 2021 was Janus Henderson Group, an estimated $1.65M sold.
Based on aggregated 13F filings for Q4 2021.